That virtually all IDH-mutant adult gliomas feature either ATRX deficiency or activating mutations in TERT2, which encodes the catalytic core of telomerase, speaks to the absolute necessity of pathological telomere maintenance across the tumor group. This evidence concerns the gene ATRX and central nervous system cancer.